Navigation Links
JDRF and the Helmsley Charitable Trust Form a Collaboration to Accelerate Innovative Type 1 Diabetes Research and Development
Date:11/2/2011

NEW YORK, Nov. 2, 2011 /PRNewswire-USNewswire/ -- JDRF and The Leona M. and Harry B. Helmsley Charitable Trust, two of the largest non-government funders of type 1 diabetes (T1D) programs, announced today that they have formalized a collaboration that will foster a new level of cooperation between the organizations. The goal of the collaboration is to accelerate the pace of research and development to deliver better treatments, devices, and diagnostics for improving the lives of people with T1D. The first two co-funded grants as part of the collaboration were also announced today.

"JDRF and the Helmsley Charitable Trust developed a close working relationship around type 1 diabetes projects over the past several years, highlighting our common commitment to this disease," says Jeffrey Brewer, President and Chief Executive Officer of JDRF. "This new collaboration strengthens our existing relationship through information sharing, streamlining, and integrating funding strategies and combining resources in those areas of type 1 diabetes where we have identified strong shared interests."

"Since 2007, the Helmsley Charitable Trust has provided $14 million to support JDRF projects for type 1 diabetes research and development," says David Panzirer, Helmsley Charitable Trust Trustee. "The new level of cooperation between our organizations will allow us to work more efficiently in areas of mutual interest.  By collaborating more closely, we will be able to leverage our resources and have a greater impact in fueling innovative results that improve the lives of people living with type 1 diabetes."

The first project to be supported by the new JDRF-Helmsley Charitable Trust collaboration is the T1D Clinical Development Research Roadmap. This program will generate a comprehensive and objective strategic plan to serve as a framework for funding decisions of clinical research involving patients with established T1D. The plan will be based on a comprehensive synthesis of knowledge regarding the current T1D clinical development landscape. The goal is to identify novel perspectives, using the available data that suggest new approaches toward achieving clinically meaningful impact in established T1D with known therapeutics. It will include strategies to effectively characterize the various stages of this disease and a review of clinical development therapy opportunities, particularly when looking at subsets of patients with T1D. The resulting plan will be shared with the T1D research and development community to serve as a common resource.

The second initiative to be supported by the collaboration is the Bioimaging Project, which is intended to develop new diagnostic technologies to non-invasively determine the presence and functional activity of insulin-producing beta cells in a person's pancreas. Known as beta cell imaging, these technologies aim to overcome one of the key challenges in the T1D field: directly assessing the cells within the pancreas that are responsible for normal insulin production. These new technologies will be an invaluable resource in multiple areas of T1D research, including early detection of diabetes; monitoring of transplanted or regenerated beta cells; monitoring certain new therapies during clinical trials; and following the progression of T1D in a person over time.

In addition, the JDRF-Helmsley Charitable Trust collaboration has launched a request for proposals to develop and deliver more accurate and reliable sensors that would measure a person's blood glucose (sugar) levels on a continuous basis. Building upon the successes of current continuous glucose monitoring technologies, this initiative seeks to advance these sensors to the next generation that would provide users with more accurate and reliable blood glucose measurements. Improved blood glucose sensors will enable T1D patients to make better insulin dosing decisions.

"JDRF and the Helmsley Charitable Trust are committed to producing results that create a positive impact in the lives of individuals with type 1 diabetes today," said Dana Ball, Helmsley T1D Program Director. "This collaborative effort is intended to advance critical research and development that will translate to better treatments and devices for people with type 1 diabetes." The JDRF-Helmsley Charitable Trust collaboration is designed to complement existing programs for each organization. Both organizations will continue to provide, manage, and maintain independent research funding efforts.

About JDRF 
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is the largest charitable supporter of T1D research. The goal of JDRF is to improve the lives of every person affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.  Since its founding in 1970, JDRF has awarded more than $1.5 billion to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. Past JDRF research efforts have helped to significantly improve the care of people with this disease and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. For more information, please visit www.jdrf.org.  

About The Leona M. and Harry B. Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust, established in 1999, is administered by four Trustees selected by Leona Helmsley. As a continuation of Mr. and Mrs. Helmsley's generous giving throughout their lifetimes, the Trust supports a diverse range of organizations with a major focus on health and medical research, in addition to programs in human services, education, cultural access, conservation and the security and development of Israel. Since 2009, the Trust has committed over $100 million to type 1 diabetes research and programs through the Helmsley Type 1 Diabetes Program. For more information, please visit www.helmsleytrust.org


'/>"/>
SOURCE Juvenile Diabetes Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Varian Medical Systems Publishes First Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements
2. CVS Caremark Charitable Trust and CVS/pharmacy Provide Over $100,000 in Disaster Relief To Communities Impacted by Hurricane Irene
3. CVS Caremark Charitable Trust Makes Initial Donation of $100,000 to Relief Effort in Japan
4. New Image Global, Inc. Partners With Limbs For U, Charitable Service Group to Provide Prosthetic Limbs in the Dominican Republic
5. Hanger Ivan R. Sabel Foundation to Receive $75,000 Donation Towards Charitable Prosthetic Efforts in Haiti from Grapes for Humanity/US
6. Hanger Orthopedic Group Honored for its Charitable Relief Efforts in Haiti by InterAction
7. ArjoHuntleigh Awarded Vascular Compression Contract With HealthTrust Purchasing Group
8. I-Flow LLC, a Kimberly-Clark Health Care Company Announces Agreement for ON-Q® Products With HealthTrust Purchasing Group
9. Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
10. Trust Your Derm: The JUVA Skin & Laser Center Advises Patients To Seek Board Certified Dermatologists and AAAHC Accredited Facilities For Safe Cosmetic Procedures
11. BioMed Realty Trust Reports Second Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... 2017  May is Stroke Awareness Month and Omron ... important methods to prevent a stroke: monitor and manage ... Control and Prevention, undetected and uncontrolled hypertension is a ... global leader in personal heart health technology, recently evolved ... attack and stroke and is advancing a national public ...
(Date:5/4/2017)... and SAN DIEGO , May ... Gynecologists (ACOG) 2017 Annual Clinical and Scientific Meeting— OBP ... illuminating medical devices, today announced the launch of a ... OfficeSPEC and ER-SPEC vaginal specula. ... of extra-small and extra-large sizes makes OBP Medical,s line ...
(Date:5/3/2017)...  Kalorama Information notes that transplant diagnostics is ... and this is projected to continue to 2021. ... or bone marrow transplants require histocompatibility between the ... this task. This according to a new report ... various PCR-based methodologies, Sanger sequencing and NGS used ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, a ... portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that provides real-time ... datacenter to the cloud to the edge. Through the new partnership, customers get ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... City (PRWEB) , ... May 23, 2017 , ... ... Population Health and Clinical Integration company, announced today that its iClinic V12.2 ... Home (PCMH) 2017 Prevalidation. NCQA recently introduced PCMH 2017 standards which emphasize ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... in North Carolina have remained steady since 2009, according to a Workers Compensation ... , The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th Edition ...
Breaking Medicine News(10 mins):